Phase 3 Colorectal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with colorectal cancer that has spread to other parts of the body (metastatic), confirmed by a tissue sample.
• People whose cancer does not have a specific genetic marker called microsatellite instability (MSI) (confirm with trial site).
• People whose cancer does not have a specific gene change called a BRAF V600E mutation.
• People who have had brain metastases that were treated, provided that follow-up brain scans show the cancer has not grown or spread further in the brain.
• People who have no signs of cancer spread to the lining of the abdomen (peritoneum) or surrounding fatty tissue (omentum); if scans suggest this may be present, a keyhole surgical procedure may be needed to confirm its absence.
• People whose original bowel tumour has already been surgically removed, or where a surgeon has confirmed it can be removed.
• People who have four or fewer separate sites where cancer has spread, based on imaging scans taken before chemotherapy started — not including cases where the cancer has spread only to the liver (at least one other site outside the liver must also be present).
• People whose spread sites can be treated using some combination of surgery, microwave ablation, or a precise form of targeted radiation called SABR, with at least one site suitable for SABR — a radiation specialist must confirm this.
• People whose cancer can be measured on scans according to standard criteria (RECIST v1.1).
• People who have received no more than 16 weeks (4 months) of chemotherapy or systemic treatment before the first stage of enrolment.
• People who have received between 16 and 24 weeks (4 to 6 months) of first-line systemic treatment for their metastatic cancer at the time of full registration.
• People whose cancer has shown no clear signs of getting worse during systemic treatment.
• People who are not considered suitable for a specific liver-directed pump treatment (hepatic artery infusion pump therapy), or where the benefit of that treatment is unclear.
• People who completed any earlier cancer treatment (such as adjuvant chemotherapy after surgery) at least 12 months before the metastatic cancer was diagnosed.
• People aged 18 or older.
• People who are well enough to carry out basic daily activities, based on a standard medical scoring scale (ECOG performance status of 0 to 2).
• People with adequate blood counts, kidney function, and liver function as measured by specific blood tests (confirm with trial site for exact values).
• People living with HIV who are on effective HIV treatment and have had an undetectable viral load within the past 6 months.
• Women of childbearing potential must have a negative pregnancy test within 14 days before registration, as the treatments involved carry known risks to a developing baby.
• People who are not pregnant and not breastfeeding.
• People who are not planning to take part in any other clinical trial at the same time.

Who may not be able to join:

• No specific exclusion criteria were listed for this trial (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.